Efficacy and safety of gene therapy in β-thalassemia and sickle cell disease: A systematic review and meta-analysis
Journal of Applied Pharmaceutical Science · 2026-04 · 16 (4) · 109-124
DOI: 10.7324/japs.2026.268821 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Applied Pharmaceutical Science, online erschienen am 01.04.2026. Verfasst von Ramnarayan Belur Krishna Prasad und 5 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
β-Thalassemia and sickle cell disease (SCD) are inherited hemoglobinopathies that pose substantial global health challenges. Gene therapy has emerged as a transformative, potentially curative approach by directly targeting the underlying genetic defects responsible for these disorders. This systematic review and meta-analysis critically assessed the clinical efficacy and safety of contemporary gene therapy modalities, including lentiviral-based platforms (e.g., Zynteglo) and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9–based approaches (e.g., Casgevy), in patients with β-thalassemia and SCD. A comprehensive literature search spanning January 2013 to March 2025 was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. Pooled analyses demonstrated a significant increase in transfusion independence among treated patients (Z = 5.89, p < 0.001), with moderate heterogeneity across studies. Lentiviral gene therapies consistently achieved haemoglobin normalisation and sustained transfusion freedom, whereas early-phase CRISPR trials highlighted favourable safety profiles and high gene-editing precision. Despite these promising outcomes, challenges such as insertional mutagenesis, off-target editing, high therapeutic costs, and limited availability in resource-constrained regions persist. In summary, gene therapy represents a clinically effective and potentially curative intervention for β-thalassemia and SCD. Nonetheless, rigorous long-term safety monitoring and strategies to enhance global accessibility are essential to ensure equitable implementation and sustainable patient outcomes.
Zitieren
APA
Prasad, R. B. K., Setlur, K. P., Annegowda, V. M., A., S. M., Nanaiah, P., & Rangan, V. (2026). Efficacy and safety of gene therapy in β-thalassemia and sickle cell disease: A systematic review and meta-analysis. Journal of Applied Pharmaceutical Science, 16(4), 109-124. https://doi.org/10.7324/japs.2026.268821
Vancouver
Prasad RBK, Setlur KP, Annegowda VM, A. SM, Nanaiah P, Rangan V. Efficacy and safety of gene therapy in β-thalassemia and sickle cell disease: A systematic review and meta-analysis. Journal of Applied Pharmaceutical Science. 2026;16(4):109-124. doi:10.7324/japs.2026.268821
BibTeX
@article{Prasad2026,
author = {Prasad, Ramnarayan Belur Krishna and Setlur, Krishnanand P. and Annegowda, Vidya M. and A., Savita Mallikarjun and Nanaiah, Pallavi and Rangan, Vinod},
title = {Efficacy and safety of gene therapy in β-thalassemia and sickle cell disease: A systematic review and meta-analysis},
journal = {Journal of Applied Pharmaceutical Science},
year = {2026},
volume = {16},
number = {4},
pages = {109--124},
doi = {10.7324/japs.2026.268821}
}
EUVIMED